Cormorant Asset Management as of Dec. 31, 2019
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 62 positions in its portfolio as reported in the December 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Mirati Therapeutics | 9.2 | $230M | 1.8M | 128.86 | |
| Reata Pharmaceuticals Inc Cl A | 8.7 | $218M | 1.1M | 204.43 | |
| Turning Point Therapeutics I | 8.4 | $212M | 3.4M | 62.29 | |
| Chemocentryx | 5.0 | $125M | 3.2M | 39.55 | |
| Principia Biopharma | 4.3 | $109M | 2.0M | 54.78 | |
| Constellation Pharmceticls I | 4.3 | $108M | 2.3M | 47.11 | |
| Ascendis Pharma A S (ASND) | 3.6 | $90M | 650k | 139.12 | |
| Bridgebio Pharma (BBIO) | 3.5 | $88M | 2.5M | 35.05 | |
| Apellis Pharmaceuticals (APLS) | 3.3 | $83M | 2.7M | 30.62 | |
| Biohaven Pharmaceutical Holding | 3.3 | $82M | 1.5M | 54.44 | |
| Axsome Therapeutics (AXSM) | 2.5 | $62M | 600k | 103.36 | |
| Crispr Therapeutics (CRSP) | 2.4 | $61M | 1.0M | 60.90 | |
| Nextcure (NXTC) | 2.2 | $56M | 1.0M | 56.33 | |
| Myokardia | 2.0 | $51M | 700k | 72.89 | |
| Stoke Therapeutics (STOK) | 2.0 | $51M | 1.8M | 28.32 | |
| Y Mabs Therapeutics (YMAB) | 2.0 | $50M | 1.6M | 31.25 | |
| SPDR S&P Biotech (XBI) | 1.9 | $48M | 500k | 95.11 | |
| Rocket Pharmaceuticals (RCKT) | 1.7 | $42M | 1.8M | 22.76 | |
| Viela Bio | 1.6 | $41M | 1.5M | 27.15 | |
| Tricida | 1.4 | $35M | 928k | 37.74 | |
| Axonics Modulation Technolog (AXNX) | 1.4 | $34M | 1.2M | 27.71 | |
| Quotient | 1.3 | $33M | 3.5M | 9.51 | |
| Sarepta Therapeutics (SRPT) | 1.3 | $32M | 250k | 129.04 | |
| Zymeworks | 1.3 | $32M | 700k | 45.46 | |
| Myovant Sciences | 1.2 | $31M | 2.0M | 15.52 | |
| Cabaletta Bio (CABA) | 1.2 | $30M | 2.1M | 13.97 | |
| Uniqure Nv (QURE) | 1.1 | $29M | 400k | 71.66 | |
| Eidos Therapeutics | 1.1 | $28M | 496k | 57.39 | |
| Allakos (ALLK) | 1.1 | $29M | 300k | 95.36 | |
| Deciphera Pharmaceuticals | 1.1 | $28M | 450k | 62.24 | |
| Amarin Corporation (AMRN) | 1.1 | $28M | 1.3M | 21.44 | |
| Blueprint Medicines (BPMC) | 1.1 | $28M | 345k | 80.11 | |
| Immunovant Inc unit 12/18/2024 (IMVTU) | 1.1 | $27M | 1.1M | 24.58 | |
| Omeros Corporation (OMER) | 0.9 | $22M | 1.5M | 14.09 | |
| Galapagos Nv- (GLPG) | 0.8 | $21M | 100k | 209.21 | |
| Satsuma Pharmaceuticals Ord | 0.7 | $17M | 858k | 19.68 | |
| Akero Therapeutics (AKRO) | 0.7 | $16M | 741k | 22.19 | |
| Argenx Se (ARGX) | 0.6 | $16M | 100k | 160.52 | |
| Twist Bioscience Corp (TWST) | 0.6 | $14M | 687k | 21.00 | |
| Merus N V (MRUS) | 0.6 | $14M | 1.0M | 14.08 | |
| Kura Oncology (KURA) | 0.6 | $14M | 1.0M | 13.75 | |
| Ra Pharmaceuticals | 0.6 | $14M | 296k | 46.93 | |
| Sorrento Therapeutics (SRNE) | 0.5 | $14M | 4.0M | 3.38 | |
| Inspire Med Sys (INSP) | 0.5 | $13M | 172k | 74.21 | |
| Eiger Biopharmaceuticals | 0.5 | $12M | 833k | 14.90 | |
| Zai Lab (ZLAB) | 0.5 | $12M | 277k | 41.59 | |
| Harpoon Therapeutics | 0.4 | $9.6M | 650k | 14.79 | |
| Arena Pharmaceuticals | 0.3 | $7.8M | 172k | 45.42 | |
| Avrobio Ord (AVRO) | 0.3 | $6.4M | 318k | 20.13 | |
| Precision Biosciences Ord | 0.3 | $6.5M | 468k | 13.89 | |
| Autolus Therapeutics Plc spon ads (AUTL) | 0.2 | $6.3M | 480k | 13.20 | |
| Anaptysbio Inc Common (ANAB) | 0.2 | $5.9M | 365k | 16.25 | |
| Igm Biosciences (IGMS) | 0.2 | $6.0M | 156k | 38.16 | |
| Atreca Inc Cl A (BCEL) | 0.2 | $5.0M | 326k | 15.47 | |
| Orchard Therapeutics Plc ads | 0.2 | $4.8M | 350k | 13.75 | |
| Gossamer Bio (GOSS) | 0.2 | $4.7M | 300k | 15.63 | |
| Neurocrine Biosciences (NBIX) | 0.2 | $4.2M | 39k | 107.48 | |
| Nektar Therapeutics (NKTR) | 0.2 | $4.3M | 200k | 21.58 | |
| Minerva Neurosciences | 0.2 | $4.3M | 608k | 7.11 | |
| X4 Pharmaceuticals (XFOR) | 0.1 | $2.7M | 253k | 10.70 | |
| Theravance Biopharma (TBPH) | 0.1 | $1.3M | 50k | 25.90 | |
| Outlook Therapeutics Inc *w exp 02/18/201 | 0.0 | $25k | 417k | 0.06 |
